People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...

Female sex, antidepressant use, and type of health insurance significantly influence semaglutide initiation. (HealthDay News) — Sociodemographic, health care, and clinical factors are associated with ...

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...

Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...

Or the mysterious relationship between osteoarthritis and obesity. Semaglutide mimics the action of the natural protein glucagon-like peptide 1(GLP-1), a hormone from a family of chemical ...

Telehealth company Hims & Hers is playing offense in a new commercial slated to air during the Super Bowl next month. | Telehealth company Hims & Hers is playing offense in a new commercial slated to ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Significant associations for semaglutide initiation included being female, using certain medication classes including antidepressants, and being covered by a point-of-service plan. (HealthDay News ...